Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Ce&Ce4med AB
AB
Active
Org 5592592017
Frejgatan 19
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2020
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2025
SEK 60K
+121% vs 2024
EBITDA margin
177.3%
+611% vs 2024
Equity ratio
62.1%
Financial strength
Net profit 2025
SEK 89K
+530% vs 2024
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
0M
0%
2025
Key figures
Annual report 2025
Revenue
SEK 60K
+121%
EBITDA
SEK 106K
+611%
Net profit
SEK 89K
+530%
Total assets
SEK 194K
+158%
Equity
SEK 121K
+282%
Employees
0
—
Company information
Legal name
Ce&Ce4med AB
Org number
5592592017
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
11 juni 2020
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2025-05-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Företaget ska bedriva rådgivning konsultation, investering och förvaltning av aktier och relaterade aktiviteter inom medicin och hälsa.
Contact
Address
Frejgatan 19
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Stockholm
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
0M
2025
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2021
0M
2022
0M
2023
0M
2024
0M
2025
Income statement
SEK thousands
Item
2021
2022
2023
2024
2025
Revenue
13
5
27
27
60
Staff expenses
—
—
−0
−14
−0
EBITDA
5
−2
−11
−21
106
Depreciation & amort.
−0
—
—
—
—
EBIT
5
−2
−11
−21
106
Net financials
—
—
−0
0
0
Profit before tax
5
−2
−11
−21
106
Tax
−1
—
—
—
−17
Net profit
4
−2
−11
−21
89
Balance sheet
SEK thousands
Item
2021
2022
2023
2024
2025
Total assets
38
40
41
75
194
Equity
29
27
27
32
121
Long-term debt
0
—
—
—
—
Short-term debt
9
12
13
44
74
Total debt
9
12
13
44
74
Financial ratios
5-year trend
EBITDA margin
177.3%
This company
15.8%
Market median
+1022% vs market
2021
2025
Equity ratio
62.1%
This company
38.2%
Market median
+63% vs market
2021
2025
Return on equity
73.8%
This company
18.4%
Market median
+301% vs market
2021
2025
Net profit margin
148.8%
This company
8.1%
Market median
+1737% vs market
2021
2025
Asset turnover
0.31×
This company
1.12×
Market median
-72% vs market
2021
2025
Debt / equity
0.61×
This company
0.62×
Market median
+2% vs market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2024-06-01 – 2025-05-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2023-06-01 – 2024-05-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2022-06-01 – 2023-05-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2021-06-01 – 2022-05-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-06-01 – 2021-05-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
GE
Gianni Ennio Celsi
Deputy Board Member
2022
SC
Sandra Ceccatelli
Board of Directors
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Ce&Ce4med AB also hold positions in
0
other companies.
Person
Role here
Other companies
Gianni Ennio Celsi
Deputy Board Member
0 companies
Sandra Ceccatelli
Board of Directors
0 companies